Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has filed a registration statement with the Securities and Exchange Commission (SEC) on September 4, 2024, for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, stock purchase contracts, stock purchase units, and subscription rights. The registration allows Illumina to offer these securities to the public from time to time, providing the company with financial flexibility for future corporate activities. The securities may be sold through underwriters, dealers, agents, or directly to investors, and the terms will be determined at the time of each offering and detailed in future prospectus supplements. Illumina's common stock is listed on the Nasdaq Global Select Market under the symbol 'ILMN.'

Illumina, Inc., a global leader in DNA sequencing and array-based technologies, has filed a registration statement with the Securities and Exchange Commission (SEC) on September 4, 2024, for the issuance of various securities, including debt securities, common stock, preferred stock, warrants, stock purchase contracts, stock purchase units, and subscription rights. The registration allows Illumina to offer these securities to the public from time to time, providing the company with financial flexibility for future corporate activities. The securities may be sold through underwriters, dealers, agents, or directly to investors, and the terms will be determined at the time of each offering and detailed in future prospectus supplements. Illumina's common stock is listed on the Nasdaq Global Select Market under the symbol 'ILMN.'